Following infection with Mycobacterium tuberculosis, the causative agent of tuberculosis
(TB), most human hosts are able to contain the infection and avoid progression to active TB …

Featured Application This comprehensive overview of drug-resistant tuberculosis will be
useful for researchers to expand their knowledge beyond mechanisms other than …

This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

Introduction Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition
needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is …

Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Objective: To review the spectrum of activity, efficacy, safety, and role in therapy of all
antibiotics and related biologics approved by the Food and Drug Administration (FDA) in the …

Objectives To evaluate the access to comprehensive diagnostics and novel antituberculosis
medicines in European countries. Methods We investigated the access to genotypic and …

Background Drug-resistant tuberculosis (DR-TB) is considered to be a public health threat
and is difficult to cure, requiring a lengthy treatment with potent, potentially toxic drugs. The …

This report provides an introduction and reference tool for tuberculosis (TB) controllers
regarding the essential components of a public health program to prevent, control, and …

Methods In June 2018, BDQ and CFZ were added to the second-line phenotypic drug
susceptibility testing (pDST) panel at the National and WHO Supranational Reference …